Kincell Bio has announced a new collaboration with RegCell, a biotechnology company developing an immune tolerance platform based on epigenetically reprogrammed regulatory T cells. Under the agreement, Kincell Bio will provide comprehensive CMC development and GMP manufacturing support to advance RegCell’s lead Treg program toward clinical trial evaluation.
